Clinical trial
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced…
NCT00266877 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00266877 |
|---|---|
| Title | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Lung Neoplasms |
| Intervention type | Drug |
| Interventions | HKI-272 |
| Enrollment | 172 |
| Start date | Dec 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Dec 19, 2005 |
| Last update posted | Apr 13, 2018 |
| Countries | France, Hungary, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: